The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanjay Nannapaneni
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts less than Nifty Smallcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sanjay Nannapaneni, a member of Natco Pharma's promoter group, sold 70,000 equity shares in the open market between 9 March and 10 March 2026 for an approximate value of Rs. 7.12 crore. His holding dropped from 2,26,910 shares (0.13%) to 1,56,910 shares (0.09%) of the company. The disclosure was filed under SEBI's insider trading and takeover regulations, and no shares were encumbered, pledged, or transferred off-market. Natco Pharma's total equity share capital remains unchanged at approximately 17.91 crore shares of Rs. 2 each.
The sale size is very small at just 0.04% of total share capital, so it is unlikely to materially affect the stock price or promoter control. Retail investors should view this as a routine, minor trim by a promoter group member and not a signal of distress or a strategic shift.